Amarin Reports Encouraging Efficacy and Safety Results from Pilot Study Treating COVID-19 ...
Press release content from Globe Newswire. The AP news staff was not involved in its creation. Amarin Reports Encouraging Efficacy and Safety Results from Pilot Study Treating COVID-19 ... Amarin Corporation plcDecember 13, 2020 GMT VASCEPA COVID-19 CardioLink-9 Randomized Trial suggests improvement in patient-reported COVID-19 symptoms while achieving its primary endpoint by demonstrating a 25% reduction in high-sensitivity C-reactive protein (hsCRP) with encouraging short-term safety and tolerability data using VASCEPA loading dose VASCEPA administration resulted in a significant 52% reduct...
Source: apnews.com